Literature DB >> 12399592

Targeting of cyclic AMP degradation to beta 2-adrenergic receptors by beta-arrestins.

Stephen J Perry1, George S Baillie, Trudy A Kohout, Ian McPhee, Maria M Magiera, Kok Long Ang, William E Miller, Alison J McLean, Marco Conti, Miles D Houslay, Robert J Lefkowitz.   

Abstract

Catecholamines signal through the beta2-adrenergic receptor by promoting production of the second messenger adenosine 3',5'-monophosphate (cAMP). The magnitude of this signal is restricted by desensitization of the receptors through their binding to beta-arrestins and by cAMP degradation by phosphodiesterase (PDE) enzymes. We show that beta-arrestins coordinate both processes by recruiting PDEs to activated beta2-adrenergic receptors in the plasma membrane of mammalian cells. In doing so, the beta-arrestins limit activation of membrane-associated cAMP-activated protein kinase by simultaneously slowing the rate of cAMP production through receptor desensitization and increasing the rate of its degradation at the membrane.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399592     DOI: 10.1126/science.1074683

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  185 in total

Review 1.  Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling.

Authors:  Carl Nathan
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 2.  Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling.

Authors:  Sudha K Shenoy; Robert J Lefkowitz
Journal:  Biochem J       Date:  2003-11-01       Impact factor: 3.857

Review 3.  The evolving role of lipid rafts and caveolae in G protein-coupled receptor signaling: implications for molecular pharmacology.

Authors:  Rennolds S Ostrom; Paul A Insel
Journal:  Br J Pharmacol       Date:  2004-08-02       Impact factor: 8.739

Review 4.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

Review 5.  Β-arrestin: a signaling molecule and potential therapeutic target for heart failure.

Authors:  Nabila Noor; Chetan B Patel; Howard A Rockman
Journal:  J Mol Cell Cardiol       Date:  2010-11-11       Impact factor: 5.000

6.  Time-dependent evolution of functional vs. remodeling signaling in induced pluripotent stem cell-derived cardiomyocytes and induced maturation with biomechanical stimulation.

Authors:  Gwanghyun Jung; Giovanni Fajardo; Alexandre J S Ribeiro; Kristina Bezold Kooiker; Michael Coronado; Mingming Zhao; Dong-Qing Hu; Sushma Reddy; Kazuki Kodo; Krishna Sriram; Paul A Insel; Joseph C Wu; Beth L Pruitt; Daniel Bernstein
Journal:  FASEB J       Date:  2015-12-16       Impact factor: 5.191

Review 7.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

Review 8.  Nanometric targeting of type 9 adenylyl cyclase in heart.

Authors:  Autumn N Marsden; Carmen W Dessauer
Journal:  Biochem Soc Trans       Date:  2019-12-20       Impact factor: 5.407

9.  β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo.

Authors:  David R Murray; Srinivas Mummidi; Anthony J Valente; Tadashi Yoshida; Naveen K Somanna; Patrice Delafontaine; Charles A Dinarello; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2011-10-08       Impact factor: 5.000

10.  β1-adrenergic receptor antagonists signal via PDE4 translocation.

Authors:  Wito Richter; Delphine Mika; Elise Blanchard; Peter Day; Marco Conti
Journal:  EMBO Rep       Date:  2013-02-05       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.